Elanco Animal Health Inc., which is headquartered in Indianapolis, has announced a restructuring plan that will eliminate 300 positions across the company and shift another 300 employees to other areas or locations.
According to a press release, Elanco says the organizational changes generate approximately $25 million in savings in 2026 and $60 million in savings in 2027.
Elanco says it is expanding its research and development presence in its new Indianapolis global headquarters and surrounding OneHealth Innovation District, while continuing to invest in its U.S.-based manufacturing footprint. Elanco will further invest in its Kansas monoclonal antibody (mAb) manufacturing facility to support innovation, particularly a major next generation immuno-therapeutic pet innovation.
However, the company says it plans to close a German animal R&D facility and reduce its manufacturing workforce.
“The combination of a favorable tax environment from the One Big Beautiful Bill Act, regulatory reform resulting in improved timelines for USDA regulatory reviews and greater certainty on tariffs has created favorable conditions for the continuation of U.S. investments in R&D and manufacturing, while bringing key innovation capabilities from Europe to the U.S.,” according to the investor report.
The company adds that it “will continue to optimize its manufacturing footprint to power its pipeline, adjust to future volume expectations and continue the organization’s productivity journey, including reducing workforce in higher-cost locations.”
Elanco says it expects its restructuring plan to deliver $200 to $250 million in adjusted EBITDA savings by 2030, with about 30% achieved in 2026.
